BioAtla Inc
NASDAQ:BCAB 4:00:00 PM EDT
| Market Cap (Intraday) | 492.91M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $9.31 |
| 50-Day MA | $7.88 |
| 200-Day MA | $5.64 |
BioAtla Inc Stock, NASDAQ:BCAB
11085 Torreyana Road, San Diego, California 92121
United States of America
Phone: +1.858.558.0708
Number of Employees: 56
Description
BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.